BioCryst Pharmaceuticals, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2008 | — | $46.4M | $22.3M |
| Dec 2009 | — | $86.3M | $41.1M |
| Jun 2010 | — | — | $14.0M |
| Sep 2010 | — | — | $11.2M |
| Dec 2010 | — | $65.5M | $13.6M |
| Mar 2011 | — | — | $31.3M |
| Jun 2011 | — | $39.3M | $17.0M |
| Sep 2011 | — | $26.0M | $22.4M |
| Dec 2011 | — | $14.8M | $16.4M |
| Mar 2012 | — | $23.2M | $27.7M |
| Jun 2012 | — | $15.7M | $21.9M |
| Sep 2012 | — | $9.8M | $24.0M |
| Dec 2012 | — | $-454.0K | $20.9M |
| Mar 2013 | — | $-2.8M | $14.8M |
| Jun 2013 | — | $-9.0M | $19.8M |
| Sep 2013 | — | $3.4M | $26.1M |
| Dec 2013 | — | $-1.1M | $21.2M |
| Mar 2014 | — | $-5.7M | $13.6M |
| Jun 2014 | — | $90.1M | $121.5M |
| Sep 2014 | — | $83.5M | $121.2M |
| Dec 2014 | — | $75.6M | $54.5M |
| Mar 2015 | — | $64.4M | $48.4M |
| Jun 2015 | — | $76.1M | $76.8M |
| Sep 2015 | — | $64.0M | $46.6M |
| Dec 2015 | — | $47.7M | $28.9M |
| Mar 2016 | — | $27.8M | $12.9M |
| Jun 2016 | — | $13.4M | $8.7M |
| Sep 2016 | — | $4.0M | $35.4M |
| Dec 2016 | $23.0M | $1.6M | $22.1M |
| Mar 2017 | $23.0M | $38.5M | $75.2M |
| Jun 2017 | $23.0M | $24.1M | $39.7M |
| Sep 2017 | $23.0M | $100.6M | $117.8M |
| Dec 2017 | $23.0M | $83.8M | $50.3M |
| Mar 2018 | $21.3M | $62.1M | $43.8M |
| Jun 2018 | $19.6M | $46.2M | $27.1M |
| Sep 2018 | $30.0M | $72.9M | $52.6M |
| Dec 2018 | $30.0M | $49.2M | $26.7M |
| Mar 2019 | $50.0M | $22.5M | $34.8M |
| Jun 2019 | $50.0M | $-9.2M | $30.8M |
| Sep 2019 | $50.0M | $-41.3M | $29.9M |
| Dec 2019 | $0 | $38.3M | $114.2M |
| Mar 2020 | $50.0M | $3.6M | $101.9M |
| Jun 2020 | $50.0M | $76.5M | $173.5M |
| Sep 2020 | $45.0M | $33.6M | $96.5M |
| Dec 2020 | $119.7M | $-19.3M | $272.1M |
| Mar 2021 | $123.0M | $-75.0M | $226.9M |
| Jun 2021 | $126.8M | $-106.1M | $210.3M |
| Sep 2021 | $132.1M | $-147.0M | $199.6M |
| Dec 2021 | $136.1M | $-107.0M | $504.4M |
| Mar 2022 | $140.2M | $-164.2M | $395.5M |
| Jun 2022 | $144.5M | $-213.2M | $272.6M |
| Sep 2022 | $223.9M | $-242.7M | $246.9M |
| Dec 2022 | $231.6M | $-294.6M | $304.8M |
| Mar 2023 | $232.5M | $-328.3M | $155.1M |
| Jun 2023 | $293.2M | $-388.7M | $146.2M |
| Sep 2023 | $298.0M | $-411.0M | $150.9M |
| Dec 2023 | $303.2M | $-455.5M | $110.6M |
| Mar 2024 | $308.5M | $-476.2M | $84.3M |
| Jun 2024 | $313.8M | $-475.6M | $78.4M |
| Sep 2024 | $314.3M | $-468.6M | $96.8M |
| Dec 2024 | $314.9M | $-475.9M | $104.7M |
| Mar 2025 | $315.4M | $-451.9M | $105.2M |
| Jun 2025 | $242.8M | $-421.6M | $88.0M |
| Sep 2025 | $194.4M | $-387.9M | $84.1M |
| Dec 2025 | $0 | $-119.2M | $89.7M |
| Mar 2026 | $395.2M | $-553.8M | $171.6M |
| Jun 2026 | $395.4M | $-454.3M | $155.0M |